Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-01-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: randomizationpatients mustradiationpatientchemotherapy
  Phrases that lowered it: participantscorticosteroidshave historyvaccinationreceived
• Sponsor's past termination rate: 21.0% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 19.4% (lowers risk) · Drug's FDA history
• Phase: 2 (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 176 (lowers risk) · Sponsor's track record
• Disease area, respiratory: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 108309 (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 27918 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 85.4% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC NCT03689855 · started 2019 · scored riskier than 81% of active trials completed
• Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC NCT04081688 · started 2019 · scored riskier than 94% of active trials terminated
• Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) NCT04173507 · started 2020 · scored riskier than 90% of active trials completed
• Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer NCT04120454 · started 2020 · scored riskier than 90% of active trials completed
• Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC NCT02492568 · started 2015 · scored riskier than 98% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.